Progyny (NASDAQ:PGNY) Upgraded at Wall Street Zen
by Jessica Moore · The Cerbat GemWall Street Zen upgraded shares of Progyny (NASDAQ:PGNY – Free Report) from a hold rating to a buy rating in a report released on Saturday morning.
A number of other brokerages also recently weighed in on PGNY. KeyCorp dropped their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a research note on Wednesday, January 21st. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price target on shares of Progyny in a report on Friday, March 6th. Canaccord Genuity Group dropped their price objective on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Finally, BTIG Research reduced their price objective on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.91.
Read Our Latest Report on Progyny
Progyny Stock Performance
Shares of PGNY stock opened at $18.64 on Friday. Progyny has a 52 week low of $16.10 and a 52 week high of $28.75. The stock has a market capitalization of $1.46 billion, a PE ratio of 28.68, a PEG ratio of 1.04 and a beta of 0.99. The stock’s fifty day moving average is $18.42 and its 200-day moving average is $21.84.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, analysts forecast that Progyny will post 1.12 earnings per share for the current fiscal year.
Insider Transactions at Progyny
In other Progyny news, EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 7,455 shares of company stock worth $129,515. Corporate insiders own 9.90% of the company’s stock.
Institutional Investors Weigh In On Progyny
A number of institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the last quarter. Amundi raised its position in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after acquiring an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the period. Finally, Walleye Capital LLC boosted its position in shares of Progyny by 6.9% in the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after purchasing an additional 780 shares during the last quarter. 94.93% of the stock is owned by institutional investors.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.